US98937L1052
US98937L1052
Zenas BioPharma, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.78B EUR | 1.61B EUR | 1.22B EUR | 1.98B EUR |
Enterprise Value | 1.36B EUR | 1.71B EUR | 986.2M EUR | 1.87B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -5.85x | -- | -- | -- |
Price to Sales | 1,776.72x | 1,607.33x | -- | -- |
Price to Book | 6.99x | 6.5x | 3.63x | 8.17x |
EV/Revenue | 1,364.97x | 1,708.62x | -- | -- |
EV/EBITDA | -4.98x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -11.9% | -18.1% | -20.13% | -8.61% |